Catherine Eckford2025-05-05T16:26:28
The biologic delivered sustained remission in adults with the inflammatory bowel disease (IBD) over the two-year study, results show.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-29T06:00:00Z
Sponsored by Lubrizol Advanced Materials Europe BV
2026-06-22T13:25:00Z
Sponsored by IMA Pharma
2026-06-29T06:00:00
Sponsored by Lubrizol Advanced Materials Europe BV
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-04-30T10:37:00
Sponsored by Shimadzu
2026-04-14T12:32:00
Sponsored by Thermo Fisher Scientific
2025-09-19T15:52:00
Sponsored by Sanner, Uwe Raupbach (Sanner)
2025-07-25T08:10:00
Sponsored by JRS Pharma and Gattefosse, European Pharmaceutical Review
Site powered by Webvision Cloud